The most cited violation in FDA drug warning letters last fiscal year was not a contamination event or a lab failure. It was the quality unit itself. Under 21 CFR 211.22, the regulation that defines what a quality organization is supposed to do, FDA cited 62 firms whose quality function failed to do its job. That was the number one finding, ahead of process validation, component testing, and batch investigations. Read it plainly: the top compliance problem in American drug manufacturing is that the people responsible for quality either were not there, were not equipped, or were not empowered.
That is a staffing story wearing an enforcement costume. And it is not limited to pharma. Defense contractors are absorbing new certification mandates, aerospace suppliers are queuing for special-process audits, and healthcare service companies are watching a federal watchdog claw back billions. In every one of these markets, the same quiet assumption does the damage: that quality and compliance roles are support hires, filled after the scientists, the engineers, and the salespeople.
The supply and demand data says the opposite. Demand for quality professionals who understand both the regulations and the operations is climbing across every regulated industry at once. Supply is thin, aging, and produced by no university pipeline. Companies that hire this talent well have fewer regulatory problems downstream, and the gap between hiring well and hiring late is measured in hundreds of millions of dollars.
The demand side: regulators got busier, and smarter
Start with the numbers coming out of FDA. An analysis of fiscal year 2025 enforcement published by Pharmaceutical Online counted 303 warning letters, up 59 percent from 190 the year before. Inspection-based letters rose from 111 to 135. FDA’s own compliance leadership confirmed the trend: the director of CDER’s Office of Compliance reported a roughly 50 percent jump in warning letters, alongside 126 import alerts.
The inspection engine behind those letters is accelerating too. Reed Smith’s review of FDA activity found the agency conducted 694 more inspections in fiscal 2025 than the prior year, and untitled letters, the warning shot before the warning letter, jumped to 58 from just 5 in fiscal 2024. In June 2025, FDA launched an AI system called Elsa that mines adverse event reports, compliance data, and Form 483 observations to decide which facilities to visit next. Targeting is no longer random. Facilities with weak quality histories rise to the top of the list.
Then came the end of the courtesy call. In May 2025, FDA announced it would expand unannounced inspections of foreign facilities. About 90 percent of prior foreign inspections were preannounced, which gave overseas plants weeks to prepare. That cushion is disappearing at the sites producing roughly 40 percent of the world’s active pharmaceutical ingredients. The practical effect for any company with a global supply chain is simple: quality has to be in inspection-ready condition every day, which is a permanent staffing requirement, not an event you surge for.
FDA publishes two decades of Form 483 observation data, fiscal 2006 through fiscal 2025, on its own website. Anyone who wants to see what investigators actually cite can download the spreadsheet. The categories barely change year to year. Procedures not followed. Investigations not completed. Quality unit not doing its job. These are people problems, and they show up wherever the people are missing.
Four industries, one squeeze
Life sciences faces the most visible pressure because FDA publishes its scorecard. The fiscal 2025 data above tells the story: more inspections, more letters, sharper targeting, and a top violation category that names the quality unit directly. Every biotech heading toward its first approval also faces a pre-approval inspection, a single high-stakes audit where a thin quality team can stall a program that cost hundreds of millions to build.
Manufacturing, especially aerospace and precision work, runs on certification frameworks that all demand credentialed quality people. AS9100 governs aerospace quality management systems. Nadcap, the industry-managed accreditation program for special processes like heat treating, welding, and nondestructive testing, now covers more than 4,500 accredited suppliers across 24 process areas, with over 60 subscribing prime manufacturers. Every one of those accreditations requires internal auditors, process owners, and quality engineers to earn and keep it. A supplier that loses accreditation loses its seat at the table with the primes.
Defense just added an entire compliance discipline. The CMMC rule, which took effect November 10, 2025, phases cybersecurity certification requirements into Defense Department contracts. By year four, roughly 338,000 entities will carry obligations, including about 230,000 small businesses, and primes must verify their subcontractors comply before sharing sensitive data. That is a compliance and quality assurance workload landing on a workforce that NDIA’s Vital Signs report already flags as strained. Workforce issues rank among the defense industrial base’s top challenges, and clearance requirements shrink the eligible pool while raising the cost of every hire.
Service industries feel the same force under a different agency’s letterhead. In its most recent semiannual report, the HHS Office of Inspector General reported $5.56 billion in expected recoveries over just six months, along with 604 criminal and civil actions and 1,212 exclusions from federal health programs. For healthcare services, revenue cycle firms, telehealth platforms, and staffing companies that touch federal dollars, the compliance officer is what the quality director is to a plant. Demand for people who can run those programs is rising with every enforcement headline.
Four industries, four rulebooks, one conclusion. The referee count went up everywhere at once, and the roster of people who can play defense did not.
The supply problem: nobody graduates as a quality person
Here is the part executives consistently underestimate. There is no degree that produces a quality professional. Universities graduate chemists, microbiologists, and mechanical engineers. Quality people are grown, not printed. The strong ones spent years on the plant floor or at the lab bench first, then layered regulation, auditing, risk judgment, and the diplomacy needed to tell a production leader no. That seasoning takes five to ten years, and no course compresses it.
The pipeline feeding that growth is shrinking at both ends. The Manufacturing Institute found nearly one quarter of the manufacturing workforce is 55 or older, and 97 percent of firms worry about losing institutional and technical knowledge as those workers retire. Quality departments skew senior, so they take that hit early. Meanwhile Deloitte and The Manufacturing Institute project the sector needs 3.8 million new employees by 2033 and could leave 1.9 million roles unfilled, about half of skilled openings. Sixty five percent of manufacturers already call attracting and retaining talent their top business challenge. Quality roles compete inside that shortage while requiring more experience than most of it.
Compensation data confirms the market has noticed even if hiring plans have not. ASQ’s 2025 salary survey, the 39th annual edition, found quality salaries rising 5.2 percent, and its clearest finding was about scope: leadership and strategic skills now drive advancement as much as technical mastery. The market is paying quality professionals more and asking them to operate as business leaders. A company still budgeting the role as a checklist administrator is bidding on a candidate who no longer exists at that price.
Defense adds one more filter. Take an already scarce quality profile, then require a clearance, and the candidate pool drops from thin to nearly empty. NDIA has documented how clearance requirements cut available talent while pushing up the cost to hire and keep it.
Why companies underinvest until the 483 lands
Quality is the classic cost center problem. When the function works, nothing happens. No recalls, no findings, no headlines. Finance sees salaries with no revenue attached, so the requisition slips a quarter, then another. The scientist gets hired first because science is the product. The engineer gets hired first because the line has to run. The quality director search waits.
Then an investigator shows up, and the math inverts violently. Redica Systems’ review of three consent decrees shows the scale. Ranbaxy and its parent paid a $500 million settlement tied to manufacturing violations. Genzyme paid a $175 million penalty under a decree that reshaped its manufacturing operations and remains in effect. McNeil shut its Fort Washington plant for more than a year of remediation. None of those figures include the quieter losses: delayed approvals, remediation consultants billed at multiples of an employee’s cost, distracted leadership, and customers who signed with a competitor while the plant was dark.
Set that against the cost of the fix. A strong quality leadership team, even paid above the ASQ benchmarks, runs a few million dollars over five years. One consent decree can cost a hundred times that. Underinvesting in quality talent is not frugal. It is a loan against future enforcement, at loan shark rates, and fiscal 2025 showed the collector is making more house calls.
What sophisticated organizations do differently
They write the role around judgment, not checklists. A quality job description that lists document review and batch record checks attracts administrators. The organizations that hire well define the role by decisions: when to stop a line, how to argue risk with an operations VP, what to say to an investigator on day one. That framing attracts the operators and lab scientists who grew into quality, which is where the real talent lives.
They build a career path so quality is not a dead end. The fastest way to lose a strong quality engineer is to show them their ceiling. Companies that keep quality talent map routes upward and sideways: quality engineer to site quality head, quality into operations leadership and back. ASQ’s data says leadership skill now drives quality careers. Give it somewhere to go.
They benchmark pay against the current market, not last year’s band. Quality compensation moved 5.2 percent in one year. Reviewing the band every two years means every offer goes out stale. The ASQ survey is published annually and broken out by role, industry, and region. Use it before the search opens, not after the second candidate declines.
They buy surge capacity instead of burning the core team. Pre-approval inspections, remediation projects, Nadcap audit preparation, and CMMC assessments are spikes, not steady state. Contract quality professionals exist precisely for these moments. The mistake is asking a lean permanent team to absorb the spike, which is how you fail the inspection and lose the team in the same quarter.
They hire before the trigger event, not after. Every company that receives a 483 suddenly discovers urgency and enters the market at the worst moment: maximum time pressure, damaged reputation with candidates, paying panic premiums. The companies with clean inspection histories staffed for them years earlier, when they could recruit calmly and choose well.
What this means for boards and CEOs
First, treat quality staffing as a risk indicator, not an overhead line. Ask for quality headcount against production volume, open requisition aging, and turnover in the quality unit the same way you review safety metrics. FDA cited the quality unit itself more than any other requirement last year. Whether yours is fully staffed is a board-level fact.
Second, fund the bench before the demographic bill arrives. With a quarter of the manufacturing workforce near retirement and quality departments skewing senior, every quality organization needs named successors and deliberate development moves for the operations and lab people who will become the next generation. Growing a quality professional takes years. Start counting backward from the retirement dates you already know.
Third, price the alternative accurately. When the quality director requisition comes up against a revenue-side hire, put the consent decree math on the same page. A $500 million settlement, a $175 million penalty, a plant dark for a year. Then let the room decide which hire is optional.
The companies that get this right do not talk about quality talent as a compliance expense. They treat it the way they treat insurance they hope never pays out, except this insurance also improves the product, speeds approvals, and keeps customers. The market for these people is tighter than most executive teams realize, and it tightens further every fiscal year the enforcement numbers climb. Hire like the inspection is already scheduled. Eventually, it is.
RX2 Solutions is a workforce solutions firm specializing in HR outsourcing, executive search, and strategic staffing. We partner with organizations to build high-performing teams through customized talent strategies, leadership placement, and scalable workforce solutions.
📞 Phone: 610.340.3490
📧 Email: info@rx2solutions.com
🌐 Website: www.rx2solutions.com
RX2 Solutions
A Respectfully Professional People Company
Get the next one of these.
We publish one piece a week on hiring, HR, and leadership in regulated industries. Written by the people running the searches.
One email a week. Unsubscribe in one click. Your address stays with us.
Working on this problem right now?
Talk to a Managing Partner. You will hear back within one business day.
Start a Conversation